
DeFloria Achieves Ground-Breaking Milestone in Botanical Drug Development
DeFloria Inc.—a joint venture between Ajna BioSciences PBC and Charlotte’s Web Holdings Inc.—announced a milestone in its development of an oral multi-cannabinoid drug for the treatment of symptoms of autism spectrum disorder (ASD). To better understand the significance of this development and the forces behind it, Cannabis Business Times spoke with Joel Stanley, CEO of Ajna BioSciences and DeFloria Chairman of the Board, and Jared Stanley, CEO of DeFloria.